{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:01:02Z","timestamp":1792166462246,"version":"4.4.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":672,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1002\/hep.26461","type":"journal-article","created":{"date-parts":[[2013,5,22]],"date-time":"2013-05-22T12:24:43Z","timestamp":1369225483000},"page":"1941-1952","source":"Crossref","is-referenced-by-count":390,"title":["Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis"],"prefix":"10.1097","volume":"58","author":[{"given":"Bart","family":"Staels","sequence":"first","affiliation":[{"name":"Institut Pasteur de Lille; Lille France"},{"name":"Inserm; UMR1011 Lille France"},{"name":"Universit\u00e9 Lille Nord de France; Lille France"},{"name":"Universit\u00e9 Droit et Sant\u00e9 de Lille; Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Rubenstrunk","sequence":"additional","affiliation":[{"name":"Genfit SA; Loos France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Noel","sequence":"additional","affiliation":[{"name":"Genfit SA; Loos France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Rigou","sequence":"additional","affiliation":[{"name":"Genfit SA; Loos France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Delataille","sequence":"additional","affiliation":[{"name":"Genfit SA; Loos France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Millatt","sequence":"additional","affiliation":[{"name":"Genfit SA; Loos France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Baron","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Lille; Lille France"},{"name":"Inserm; UMR1011 Lille France"},{"name":"Universit\u00e9 Lille Nord de France; Lille France"},{"name":"Universit\u00e9 Droit et Sant\u00e9 de Lille; Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lucas","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Lille; Lille France"},{"name":"Inserm; UMR1011 Lille France"},{"name":"Universit\u00e9 Lille Nord de France; Lille France"},{"name":"Universit\u00e9 Droit et Sant\u00e9 de Lille; Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tailleux","sequence":"additional","affiliation":[{"name":"Institut Pasteur de Lille; Lille France"},{"name":"Inserm; UMR1011 Lille France"},{"name":"Universit\u00e9 Lille Nord de France; Lille France"},{"name":"Universit\u00e9 Droit et Sant\u00e9 de Lille; Lille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean W.","family":"Hum","sequence":"additional","affiliation":[{"name":"Genfit SA; Loos France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology; Pitie-Salpetriere University Hospital, University Pierre et Marie Curie Paris VI; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology; l'Institut du Thorax, Nantes University Hospital; Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9my","family":"Hanf","sequence":"additional","affiliation":[{"name":"Genfit SA; Loos France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2013,10,29]]},"reference":[{"key":"10.1002\/hep.26461-BIB0001|hep26461-cit-0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/MOG.0b013e328337b0c4","article-title":"Recent advances in nonalcoholic fatty liver disease","volume":"26","author":"Cheung","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1002\/hep.26461-BIB0002|hep26461-cit-0002","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1002\/hep.26461-BIB0003|hep26461-cit-0003","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jhep.2004.11.027","article-title":"NASH: a hidden and silent fibroser finally revealed?","volume":"42","author":"Ratziu","year":"2005","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26461-BIB0004|hep26461-cit-0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26461-BIB0005|hep26461-cit-0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1053\/jhep.2002.33324","article-title":"Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis","volume":"35","author":"Ratziu","year":"2002","journal-title":"Hepatology"},{"key":"10.1002\/hep.26461-BIB0006|hep26461-cit-0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/gast.2002.34168","article-title":"Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma","volume":"123","author":"Bugianesi","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26461-BIB0007|hep26461-cit-0007","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1756283X09359964","article-title":"Treatment options for nonalcoholic fatty liver disease","volume":"3","author":"Lam","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1002\/hep.26461-BIB0008|hep26461-cit-0008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756283X11403809","article-title":"The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis","volume":"4","author":"Wagner","year":"2011","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1002\/hep.26461-BIB0009|hep26461-cit-0009","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.semcdb.2012.01.003","article-title":"PPARs: fatty acid sensors controlling metabolism","volume":"23","author":"Poulsen","year":"2012","journal-title":"Semin Cell Dev Biol"},{"key":"10.1002\/hep.26461-BIB0010|hep26461-cit-0010","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","article-title":"Roles of PPARs in NAFLD: potential therapeutic targets","volume":"1821","author":"Tailleux","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/hep.26461-BIB0011|hep26461-cit-0011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1002\/hep.26461-BIB0012|hep26461-cit-0012","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/01.ATV.0000204327.96431.9a","article-title":"Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence","volume":"26","author":"Zambon","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1002\/hep.26461-BIB0013|hep26461-cit-0013","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1210\/en.2007-0014","article-title":"Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation","volume":"148","author":"Stienstra","year":"2007","journal-title":"Endocrinology"},{"key":"10.1002\/hep.26461-BIB0014|hep26461-cit-0014","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3945\/jn.110.135210","article-title":"PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver","volume":"141","author":"Abdelmegeed","year":"2011","journal-title":"J Nutr"},{"key":"10.1002\/hep.26461-BIB0015|hep26461-cit-0015","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jhep.2005.10.033","article-title":"Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates","volume":"44","author":"Shiri-Sverdlov","year":"2006","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26461-BIB0016|hep26461-cit-0016","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/ATVBAHA.110.220525","article-title":"Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice","volume":"31","author":"Lalloyer","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1002\/hep.26461-BIB0017|hep26461-cit-0017","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1073\/pnas.0511253103","article-title":"PPARdelta regulates glucose metabolism and insulin sensitivity","volume":"103","author":"Lee","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/hep.26461-BIB0018|hep26461-cit-0018","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab"},{"key":"10.1002\/hep.26461-BIB0019|hep26461-cit-0019","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"Cariou","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1002\/hep.26461-BIB0020|hep26461-cit-0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1172\/JCI2673","article-title":"Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2","volume":"102","author":"Sullivan","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1002\/hep.26461-BIB0021|hep26461-cit-0021","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.3748\/wjg.v18.i19.2300","article-title":"Animal models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"18","author":"Takahashi","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1002\/hep.26461-BIB0022|hep26461-cit-0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0248-4900(05)80176-5","article-title":"Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR)","volume":"77","author":"Dreyer","year":"1993","journal-title":"Biol Cell"},{"key":"10.1002\/hep.26461-BIB0023|hep26461-cit-0023","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2003.50307","article-title":"Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice","volume":"38","author":"Ip","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/hep.26461-BIB0024|hep26461-cit-0024","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1440-1746.2011.06939.x","article-title":"Peroxisome proliferator-activated receptor-alpha agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis","volume":"27","author":"Larter","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1002\/hep.26461-BIB0025|hep26461-cit-0025","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/carcin\/21.4.823","article-title":"Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis","volume":"21","author":"Peters","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1002\/hep.26461-BIB0026|hep26461-cit-0026","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1002\/hep.26461-BIB0027|hep26461-cit-0027","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1002\/hep.26461-BIB0028|hep26461-cit-0028","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejphar.2006.02.028","article-title":"Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet","volume":"536","author":"Nagasawa","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/hep.26461-BIB0029|hep26461-cit-0029","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1210\/en.2010-1468","article-title":"The PPARbeta\/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation","volume":"152","author":"Barroso","year":"2011","journal-title":"Endocrinology"},{"key":"10.1002\/hep.26461-BIB0030|hep26461-cit-0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/gast.2003.50015","article-title":"Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells","volume":"124","author":"Hellemans","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26461-BIB0031|hep26461-cit-0031","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs227","article-title":"Activation of intestinal peroxisome proliferator-activated receptor-alpha increases high-density lipoprotein production","author":"Colin","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1002\/hep.26461-BIB0032|hep26461-cit-0032","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/hep.1840380427","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1002\/hep.26461-BIB0033|hep26461-cit-0033","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2006.05.005","article-title":"Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement","volume":"4","author":"Lutchman","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1002\/hep.26461-BIB0034|hep26461-cit-0034","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.26461-BIB0035|hep26461-cit-0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"key":"10.1002\/hep.26461-BIB0036|hep26461-cit-0036","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.26461-BIB0037|hep26461-cit-0037","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/hep.26461-BIB0038|hep26461-cit-0038","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J Hepatol"},{"key":"10.1002\/hep.26461-BIB0039|hep26461-cit-0039","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00125-007-0698-9","article-title":"Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus","volume":"50","author":"Bajaj","year":"2007","journal-title":"Diabetologia"},{"key":"10.1002\/hep.26461-BIB0040|hep26461-cit-0040","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"10.1002\/hep.26461-BIB0041|hep26461-cit-0041","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","article-title":"Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study","volume":"22","author":"Athyros","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/hep.26461-BIB0042|hep26461-cit-0042","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fernandez-Miranda","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1002\/hep.26461-BIB0043|hep26461-cit-0043","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"96","author":"Bays","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1002\/hep.26461-BIB0044|hep26461-cit-0044","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db07-1318","article-title":"Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men","volume":"57","author":"Riserus","year":"2008","journal-title":"Diabetes"},{"key":"10.1002\/hep.26461-BIB0045|hep26461-cit-0045","doi-asserted-by":"crossref","DOI":"10.2337\/dc12-2012","article-title":"The dual PPAR\u03b1\/\u03b4 agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","author":"Cariou","year":"2013","journal-title":"Diabetes Care"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26461","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/hep.26461\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T07:41:49Z","timestamp":1673422909000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hep.26461"}},"subtitle":["Hepatology"],"short-title":[],"issued":{"date-parts":[[2013,10,29]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26461","archive":["Portico"],"relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10,29]]}}}